| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Xianxian Huang, Jing Liu, Guangquan Peng, Mingyue Lu, Zhongbo Zhou, Neng Jiang, Zhiming Ya. Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges. The Journal of endocrinology. vol 262. issue 3. 2024-07-22. PMID:38916409. |
glucagon-like peptide 1 (glp-1), an endogenous peptide secreted by enteroendocrine l-cells, demonstrates exceptional pharmacological potential for the treatment of t2dm and obesity, primarily through its pivotal roles in regulating glucose homeostasis, stimulating glucose-dependent insulin secretion, and promoting satiety. |
2024-07-22 |
2024-07-25 |
Not clear |
| Jordan Siu Fung Chan, Tanin Shafaati, John R Usshe. Incretin-mediated control of cardiac energy metabolism. The Journal of endocrinology. 2024-07-16. PMID:39013412. |
glucose-dependent insulinotropic polypeptide (gip) and glucagon-like-peptide-1 (glp-1) are incretin hormones that stimulate insulin secretion and improve glycemic control in individuals with type 2 diabetes (t2d). |
2024-07-16 |
2024-07-19 |
Not clear |
| Jordan Siu Fung Chan, Tanin Shafaati, John R Usshe. Incretin-mediated control of cardiac energy metabolism. The Journal of endocrinology. 2024-07-16. PMID:39013412. |
not only do gip and glp-1 increase the secretion of insulin, they may also modify glucagon secretion, both of which have potent actions on cardiac substrate utilization. |
2024-07-16 |
2024-07-19 |
Not clear |
| Wael Halloum, Yousef Al Dughem, Dagmar Beier, Lanfranco Pelles. Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review. The journal of headache and pain. vol 25. issue 1. 2024-07-13. PMID:38997662. |
glucagon-like peptide-1 (glp-1) plays a crucial role in metabolic disorders by enhancing insulin secretion, inhibiting glucagon release, and slowing gastric emptying, thereby improving glycemic control. |
2024-07-13 |
2024-07-15 |
Not clear |
| Kanako Kato, Teruo Jojima, Takahiko Kogai, Dai Tanuma, Takafumi Niitani, Shintaro Sakurai, Toshie Iijima, Takuya Tomaru, Isao Usui, Yoshimasa As. Diabetes with GLP-1R polymorphism (rs3765467) accompanied by myotonic dystrophy: A case of myotonic dystrophy with p.R131Q polymorphism at the glucagon-like peptide-1 receptor (rs3765467) resulting in marked effects of its agonist, dulaglutide. The American journal of the medical sciences. 2024-07-10. PMID:38986908. |
however, adding a glp-1 receptor (glp-1r) agonist markedly improved blood glucose levels, resulting in eventual insulin withdrawal. |
2024-07-10 |
2024-07-13 |
Not clear |
| Kanako Kato, Teruo Jojima, Takahiko Kogai, Dai Tanuma, Takafumi Niitani, Shintaro Sakurai, Toshie Iijima, Takuya Tomaru, Isao Usui, Yoshimasa As. Diabetes with GLP-1R polymorphism (rs3765467) accompanied by myotonic dystrophy: A case of myotonic dystrophy with p.R131Q polymorphism at the glucagon-like peptide-1 receptor (rs3765467) resulting in marked effects of its agonist, dulaglutide. The American journal of the medical sciences. 2024-07-10. PMID:38986908. |
this variant is known to be associated with increased endogenous insulin from beta cells in response to exogenous glp-1 infusion. |
2024-07-10 |
2024-07-13 |
Not clear |
| Mustafa Arici, Bulent Altun, Mustafa Araz, Aysegul Atmaca, Tevfik Demir, Tevfik Ecder, Galip Guz, Dilek Gogas Yavuz, Alaattin Yildiz, Temel Yilma. The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials. Frontiers in medicine. vol 11. 2024-07-01. PMID:38947237. |
specifically, perspectives on inclusion of patients with preserved estimated glomerular filtration rate (egfr) or high albuminuria, concomitant use of sodium-glucose co-transporter-2 inhibitor (sglt2i) or glucagon-like peptide 1 receptor agonist (glp-1 ra), baseline glycated hemoglobin (hba1c) level and insulin treatment, clinically meaningful heart failure outcomes and treatment-induced hyperkalemia were addressed. |
2024-07-01 |
2024-07-03 |
Not clear |
| Mustafa Arici, Bulent Altun, Mustafa Araz, Aysegul Atmaca, Tevfik Demir, Tevfik Ecder, Galip Guz, Dilek Gogas Yavuz, Alaattin Yildiz, Temel Yilma. The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials. Frontiers in medicine. vol 11. 2024-07-01. PMID:38947237. |
finerenone has emerged as a new therapeutic agent that slows dkd progression, reduces albuminuria and risk of cardiovascular complications, regardless of the baseline hba1c levels and concomitant treatments (sglt2i, glp-1 ra, or insulin) and with a favorable benefit-risk profile. |
2024-07-01 |
2024-07-03 |
Not clear |
| Rongfei Wang, Salamu Mijiti, Qilin Xu, Yile Liu, Chaolun Deng, Jiangtao Huang, Abudoukeyimu Yasheng, Yunping Tian, Yanlong Cao, Yonghui S. The Potential Mechanism of Remission in Type 2 Diabetes Mellitus After Vertical Sleeve Gastrectomy. Obesity surgery. 2024-07-01. PMID:38951388. |
the alterations in the gastrointestinal tract following vsg may improve insulin secretion and resistance by increasing incretin secretion (especially glp-1), modifying the gut microbiota composition, and through mechanisms dependent on weight loss. |
2024-07-01 |
2024-07-04 |
Not clear |
| Senthil Vel Rajan Rajaram Manoharan, Rohit Mada. GLP-1 Agonists Can Affect Mood: A Case of Worsened Depression on Ozempic (Semaglutide). Innovations in clinical neuroscience. vol 21. issue 4-6. 2024-06-28. PMID:38938530. |
glucagon-like peptide-1 (glp-1) receptor agonists have garnered significant attention in diabetes management, and they act by mimicking the effects of glp-1, a hormone that regulates insulin secretion and appetite. |
2024-06-28 |
2024-06-30 |
Not clear |
| C Samhani, B Guerci, C Laros. Cutaneous hypersensitivity reaction to dulaglutide: a case report of an allergic reaction. Diabetes & metabolism. 2024-06-28. PMID:38942076. |
glp-1 (glucagon-like peptide-1) receptor agonists are a class of anti-diabetic agents that act by inducing insulin secretion and inhibiting glucagon release in a glucose-dependent manner. |
2024-06-28 |
2024-07-01 |
Not clear |
| Ferenc Sztanek, László Imre Tóth, Attila Pető, Marcell Hernyák, Ágnes Diószegi, Mariann Harang. New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes-Beyond and within GLP-1 Receptor Agonists. Biomedicines. vol 12. issue 6. 2024-06-27. PMID:38927527. |
incretin-based peptides exert their effect through g-protein-coupled receptors, the receptors for glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip), and glucagon peptide hormones are important regulators of insulin secretion and energy metabolism. |
2024-06-27 |
2024-06-29 |
Not clear |
| Anastasios Lymperopoulos, Jordana I Borges, Renee A Stoicov. Cyclic Adenosine Monophosphate in Cardiac and Sympathoadrenal GLP-1 Receptor Signaling: Focus on Anti-Inflammatory Effects. Pharmaceutics. vol 16. issue 6. 2024-06-27. PMID:38931817. |
glucagon-like peptide-1 (glp-1) is a multifunctional incretin hormone with various physiological effects beyond its well-characterized effect of stimulating glucose-dependent insulin secretion in the pancreas. |
2024-06-27 |
2024-06-29 |
Not clear |
| Hussain Sohail Rangwala, Hareer Fatima, Mirha Ali, Muhammad Saqlain Mustafa, Muhammad Ashir Shafique, Burhanuddin Sohail Rangwala, Syed Raza Abba. Evaluating the effectiveness and safety of various Tirzepatide dosages in the management of Type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials. Journal of diabetes and metabolic disorders. vol 23. issue 1. 2024-06-27. PMID:38932909. |
titrzepatide (tzp), a dual gip and glp-1 receptor agonist, proves highly effective in controlling hyperglycemia, stimulating insulin secretion, and promoting weight loss. |
2024-06-27 |
2024-06-29 |
Not clear |
| Hussain Sohail Rangwala, Hareer Fatima, Mirha Ali, Muhammad Saqlain Mustafa, Muhammad Ashir Shafique, Burhanuddin Sohail Rangwala, Syed Raza Abba. Evaluating the effectiveness and safety of various Tirzepatide dosages in the management of Type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials. Journal of diabetes and metabolic disorders. vol 23. issue 1. 2024-06-27. PMID:38932909. |
tzp, holds promise as a treatment for dm2, surpassing insulin and glp-1. |
2024-06-27 |
2024-06-29 |
Not clear |
| Özge Ünsal, Z Selin Bacaksiz, Vladislav Khamraev, Vittorio Montanari, Martin Beinborn, Krishna Kuma. Prolonged Activation of the GLP-1 Receptor via Covalent Capture. ACS chemical biology. 2024-06-27. PMID:38935975. |
the incretin gut hormone glucagon-like peptide-1 (glp-1) has become a household name because of its ability to induce glucose-dependent insulin release with accompanying weight loss in patients. |
2024-06-27 |
2024-06-30 |
Not clear |
| Jorge D Oldan, Paula G Landman, Jennifer A Schroeder, Amir H Khandani, Lilja B Solnes, Carrie B Lee, Steven P Row. FDG PET in a Patient on a GLP-1 Agonist/Insulin Secretagogue. Clinical nuclear medicine. 2024-06-24. PMID:38914020. |
with the increase in use of glp-1 receptor agonists such as semaglutide (ozempic, wegovy, rybelsus) in the population, nuclear medicine physicians should be aware of the possibility of nondiagnostic fdg pet scans due to these medications, which work partly by increasing insulin secretion. |
2024-06-24 |
2024-06-27 |
Not clear |
| Arne Astru. Reflections on the discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directions. European journal of clinical nutrition. 2024-06-18. PMID:38890501. |
scientists were chasing an incretin hormone, and when glp-1 was finally discovered, we found that it had a pronounced satiety effect, slowed down gastric emptying, and actually reduced postprandial insulin response. |
2024-06-18 |
2024-06-21 |
Not clear |
| Zonghao Yue, Feiyue Zhao, Yuqi Guo, Yidan Zhang, Yanjuan Chen, Le He, Lili L. Food & function. vol 15. issue 12. 2024-06-17. PMID:38804210. |
chronic low-dose aa exposure increased the blood glucose level and decreased serum insulin and glp-1 levels, whereas dulaglutide treatment decreased the blood glucose level and increased the serum insulin level in aa-exposed mice. |
2024-06-17 |
2024-06-19 |
mouse |
| Alexander C Hill, Prasanna Santhanam, Caroline B Samples, Roberto Mitsui Akagi, Tariq Latif, Rodhan Khthi. Titration of Basal and Prandial Insulin Doses With the Initiation of Glucagon-Like Peptide-1 Receptor Agonist Therapy. Cureus. vol 16. issue 5. 2024-06-10. PMID:38854306. |
objective glucagon-like peptide-1 receptor agonists (glp-1 ras) have demonstrated significant efficacy in improving glycemic control in type 2 diabetes mellitus, which often results in decreased insulin dose requirements. |
2024-06-10 |
2024-06-14 |
Not clear |